E Vadai
Overview
Explore the profile of E Vadai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E, et al.
Br J Cancer
. 2007 Dec;
97(12):1655-63.
PMID: 18071348
D(b-/-)xbeta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/D(b)-beta2m single chain (HHD mice) are an effective biological tool to evaluate the antitumour cytotoxic T-lymphocyte response of known major histocompatibility-restricted...
2.
Stepensky D, Tzehoval E, Vadai E, Eisenbach L
Clin Exp Immunol
. 2005 Dec;
143(1):139-49.
PMID: 16367945
Due to the fact that many cellular proteins are extensively glycosylated, processing and presentation mechanisms are expected to produce a pool of major histocompatibility complex (MHC) class I-bound protein-derived peptides,...
3.
Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, et al.
Br J Cancer
. 2004 Jun;
91(2):398-407.
PMID: 15213716
Bladder carcinoma is the fourth most common cancer in men and the eighth most common cancer among women. Our study is aimed to characterise tumour-associated antigen peptides of transitional cell...
4.
Tirosh B, Fridkin M, Tzehoval E, Vadai E, Lemonnier F, Eisenbach L
J Immunother
. 2001 Feb;
23(6):622-30.
PMID: 11186150
The development of a cell-free synthetic vaccine to induce an effective cytotoxic T lymphocyte response is an important challenge in T-cell--mediated immunity. Because standard vaccinations with nominal epitopes were found...
5.
Carmon L, Tzehoval E, Tirosh B, Bar-Haim E, Vadai E, Feldman M, et al.
J Immunother
. 2000 Jun;
23(3):344-52.
PMID: 10838663
Peptide vaccination of homozygous mice against syngeneic tumors using single major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocyte (CTL) epitopes elicits effective immune responses against metastatic growth. So far,...
6.
Tzehoval E, Vadai E, Feldman M, Eisenbach L
J Interferon Cytokine Res
. 2000 Jan;
19(12):1391-401.
PMID: 10638708
Development of cytokine gene-modified autologous tumor vaccines must take into account the strictly paracrine physiology of cytokines whose expression at the tumor microenvironment is important for the successful induction of...
7.
Tirosh B, Popovic D, Carmon L, Tzehoval E, Vadai E, Feldman M, et al.
Int J Cancer
. 2000 Jan;
85(2):236-42.
PMID: 10629083
CTLs specific for tumor antigens play a major role in immunity against cancer. Improved binding affinity of putative TAA peptides could enhance the in vivo immunogenicity of these self-altered self-...
8.
Tirosh B, el-Shami K, Vaisman N, Carmon L, Bar-Haim E, Vadai E, et al.
Immunol Lett
. 1999 Nov;
70(1):21-8.
PMID: 10541048
CTL induction by immunization with synthetic peptide epitopes has been shown to inhibit tumor growth and its metastatic spread. Ex vivo pulsing of peptides on MHC class I-bearing cells such...
9.
el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, et al.
Eur J Immunol
. 1999 Oct;
29(10):3295-301.
PMID: 10540341
Epitope spreading is a process whereby epitopes distinct from and non-cross-reactive with an inducing epitope become targets of an evolving immune response. This phenomenon has been associated most notably with...
10.
Popovic D, Vadai E, Feldman M, Tzehoval E, Eisenbach L
Clin Exp Metastasis
. 1999 Feb;
16(7):623-32.
PMID: 9932609
Interleukin 12 (IL-12) is a disulfide-linked heterodimer molecule produced predominantly by professional antigen presenting cells. It promotes the induction of sundry biological effects with significant relevance to antitumor immunity, such...